We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GATX:NYSEGATX Corporation Analysis

Data as of 2026-04-05 - not real-time

$174.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

GATX is trading at $174.3, comfortably above its 200‑day SMA (168) but still below the 50‑day SMA (180), indicating a short‑term pull‑back within a longer‑term uptrend. The MACD histogram has turned positive and the RSI sits near 52, suggesting neutral momentum with a slight bullish tilt. Valuation metrics are attractive: the trailing P/E of 19.1 is well under the industry average of 28.9 and the forward P/E of 15.6 points to earnings expansion. The dividend yield of 1.5% is supported by a modest 27% payout ratio and solid operating cash flow, despite a negative free‑cash‑flow figure. However, the balance sheet is a concern – total debt exceeds $12 billion and the debt‑to‑equity ratio is above 300%, while free cash flow remains deeply negative. Recent analyst sentiment turned cautious, highlighted by Citigroup’s downgrade to neutral, but the consensus target price of $215.5 implies a ~24% upside.
Overall, GATX offers a blend of value and growth attributes: strong margins, revenue growth of ~8½% and a sizable upside potential, tempered by leverage and cash‑flow constraints. The stock’s low beta and stable volume suggest limited market‑wide volatility, while its diversified geographic footprint mitigates regional risk. Investors should weigh the attractive valuation and dividend against the high debt load when forming a view.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram and price above 200‑day SMA
  • Proximity to resistance near $180
  • High leverage and negative free cash flow

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to industry P/E and target price upside
  • Revenue and earnings growth with solid margins
  • Sustainable dividend and low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating margins and cash flow generation
  • Continued dividend support
  • Elevated debt burden that could limit upside

Key Metrics & Analysis

Financial Health

Revenue Growth8.60%
Profit Margin19.15%
P/E Ratio19.1
ROE10.97%
ROA2.25%
Debt/Equity349.83
P/B Ratio2.2
Op. Cash Flow$648.1M
Free Cash Flow$-4987049984
Industry P/E28.9

Technical Analysis

TrendNeutral
RSI51.7
Support$163.14
Resistance$180.10
MA 20$170.16
MA 50$180.46
MA 200$168.02
MACDBullish
VolumeStable
Fear & Greed Index78.8

Valuation

Target Price$215.50
Upside/Downside23.64%
GradeUndervalued
TypeBlend
Dividend Yield1.51%

Risk Assessment

Beta0.54
Volatility25.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.